Jeff Yass’s Crinetics Pharmaceuticals CRNX Stock Holding History

Jeff Yass’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.55M	Buy	41,400 +8,800	+27%	+$327K	﹤0.01%	7076
2026 Q1	$1.18M	Sell	32,600 -365,800	-92%	-$16.3M	﹤0.01%	7454
2025 Q4	$18.5M	Buy	398,400 +154,500	+63%	+$6.88M	﹤0.01%	2296
2025 Q3	$10.2M	Buy	+243,900	New	+$7.8M	﹤0.01%	3018
2025 Q1	–	Sell	-10,800	Closed	-$552K	–	12599
2024 Q4	$552K	Sell	10,800 -900	-8%	-$50.4K	﹤0.01%	8428
2024 Q3	$598K	Sell	11,700 -17,300	-60%	-$892K	﹤0.01%	8038
2024 Q2	$1.3M	Sell	29,000 -147,200	-84%	-$6.8M	﹤0.01%	5979
2024 Q1	$8.25M	Sell	176,200 -87,300	-33%	-$3.42M	﹤0.01%	2897
2023 Q4	$9.38M	Buy	263,500 +142,000	+117%	+$4.35M	﹤0.01%	2719
2023 Q3	$3.61M	Buy	+121,500	New	+$2.5M	﹤0.01%	4068

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

California State Teachers Retirement System (CalSTRS) West Sacramento, California $782B AUM 28.39% 1-Year Est. Return

Jeff Yass's CRNX Position: Q2 2026 in Review

Jeff Yass reduced its Crinetics Pharmaceuticals (CRNX) stake by 24% in Q2 2026, selling an estimated $411K and leaving 35,192 shares worth $1.32M. The position accounts for ﹤0.01% of the portfolio, ranked #7492.

Jeff Yass first reported a position in CRNX in Q3 2021 and has held it in 20 quarters since. The position peaked at $10.7M in Q3 2025. 265 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Jeff Yass held 35,192 shares of Crinetics Pharmaceuticals worth $1.32M as of Q2 2026.
Jeff Yass sold 11,061 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $411K.
Crinetics Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #7492 holding.
Jeff Yass first reported a position in Crinetics Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
Jeff Yass's Crinetics Pharmaceuticals position peaked at $10.7M in Q3 2025.
265 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.